The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis

Table 1 Transfusion rates, hemoglobin levels, reticulocyte counts, and changes in spleen volume before and after ESA

Pt	Transfusion rate, units PRBC/month			Hemoglobin value, g/L			Reticulocyte count, ×10⁹/L			Spleen volume, L
	BL	Before ESA^a	After ESA^b	BL	Before ESA^c	After ESA^d	BL	Before ESA^c	After ESA^d	BL	Change from BL (%)
	BL	Before ESA^a	After ESA^b	BL	Before ESA^c	After ESA^d	BL	Before ESA^c	After ESA^d	BL	Before ESA^e	After ESA^f
1	0	2.9	2.9	106	62	69	116.9	42.5	41	2.48	−13	−20
2	0.7	2.2	10.7	99	75	60	144.9	110	114.3	3.47	−22	NA
3	0.7	1.8	0.7	100	62	NA	162.1	90	NA	2.29	−29	NA
4	0	0	0.7	121	68	66	98.1	61	64	1.79	−8	−15
5	2.9	2.9	0	90	74	40	96	167	120.3	3.43	+11	−3
6	1.4	0.7	2.2	83	67	73	81.1	74	NA	3.07	−3	NA
7	0	0	0	144	78	88	156.4	39	96.1	3.04	−36	−50
8	0	0	0	93	81	80	138	82	73.4	5.24	−45	−34
9	0	0	0	90	76	78	66.9	42	42.5	2.53	−65	−67
10	0	0	0	86	74	91	92.1	49	75.7	0.46	−54	−58
11	0	0	0	92	76	73	141	106	74.9	3.16	−13	−20
12	0	0	0	90	87	84	283.2	247	205.2	2.07	−22	NA
13	0	0	0	89	84	86	57.1	32	34.6	2.15	−29	−44
Median	0.7	2	1.45	92	75	78	138.0	78	52.5	2.53	−22	−34
Min	0.0	0.0	0.0	83.0	62.0	60.0	96.0	32.0	41.0	0.46	−65.0	−67.0
Max	2.9	2.9	10.7	144.0	87.0	91.0	141.0	247.0	64.0	5.24	11.0	−3.0

BL baseline, ESA erythropoiesis-stimulating agent, max maximum, min minimum, NA no assessment available, PRBC packed red blood cell, pt patient
^aChange in PRBC transfusions 12 weeks before the first administration of ESA
^bChange in PRBC transfusions 12 weeks after the first administration of ESA
^cChange in the worst hemoglobin value and the highest reticulocyte count measured 6 weeks prior to the first administration of ESA
^dChange in the worst hemoglobin value and the highest reticulocyte count measured 12 weeks after the first administration of ESA
^ePercentage change in spleen volume from baseline to the last assessment prior to the first administration of ESA
^fPercentage change in spleen volume from baseline to the first assessment after the first administration of ESA

ISSN: 2162-3619